HOUSTON: Innovation has always been the blood pumping through the body of the pharmaceutical industry, but in recent years the supply seemed to be getting poorer.
Yet now a slew of breakthroughs in treatment for diseases like Hepatitis C, Ebola, malaria and even Alzheimer’s, the memory-destroying condition on which much time and effort has been spent to little avail so far, has prompted hope of an era of new ideas and treatments in the industry.
So is this a new start for big pharma, mired for years in a cycle of patent expiries and chasing new blockbuster drugs which disappointed, or a false dawn?
“The traditional blockbuster model doesn’t work any more,” Luca Raffellini, director of consulting, business & financial services at Frost & Sullivan, said…